Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT-NAC: N-acetylcysteine in Acute Infections or Sepsis with Liver Dysfunction
NCT07273071Phase 4Recruiting
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in sepsis, acute infection and Infection comparing N-acetylcysteine with Placebo (normal saline) (2 arms). Primary endpoint: Days alive and out of hospital at 14 days. Started Sep 2026; status: recruiting.
02
Drugs
acetylcysteine
03
Conditions
sepsisacute infectionInfection
Beyond the preview
Go deeper on NCT07273071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07273071.